Evidence map›Paper›PMID 39480071›Full record

ArticleAntimicrobial agents and chemotherapy2024

Targeted delivery of flagellin by nebulization offers optimized respiratory immunity and defense against pneumococcal pneumonia.

Mara Baldry, Charlotte Costa, Yasmine Zeroual, Delphine Cayet, Jeoffrey Pardessus, Daphnée Soulard, Frédéric Wallet, Delphine Beury, David Hot, Ronan MacLoughlin and 3 more

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mara Baldry *Univ. Lille CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, Lille, France.ORCID 0000-0001-6005-1078
Charlotte Costa *Univ. Lille CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, Lille, France.
Yasmine Zeroual *Univ. Lille CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, Lille, France.
Delphine CayetUniv. Lille CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, Lille, France.
Jeoffrey PardessusINSERM, Respiratory Disease Research Centre, Tours, France.
Daphnée SoulardUniv. Lille CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, Lille, France.
Frédéric WalletUniv. Lille CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, Lille, France.
Delphine BeuryUniv. Lille CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41 - UAR 2014 - PLBS - Plateformes Lilloises de Biologie & Santé, Lille, France.
David HotUniv. Lille CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41 - UAR 2014 - PLBS - Plateformes Lilloises de Biologie & Santé, Lille, France.ORCID 0000-0002-2361-0616
Ronan MacLoughlinAerogen IDA Business Park, Dangan, Galway, Ireland.
Nathalie Heuzé-Vourc'h *INSERM, Respiratory Disease Research Centre, Tours, France.
Jean-Claude Sirard *Univ. Lille CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, Lille, France.ORCID 0000-0001-9854-4652
Christophe Carnoy *Univ. Lille CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, Lille, France.

Funding

Agence Nationale de la Recherche (ANR) grant ANR-19-CE18- 0030-01EC | Horizon 2020 Framework Programme (H2020) project FAIR
6 · The paper itself

Abstract

Novel therapeutic strategies are urgently needed to combat pneumonia caused by

Indexed as

Anti-Bacterial AgentsFlagellinNebulizers and VaporizersPneumonia, PneumococcalStreptococcus pneumoniaeAdministration, InhalationAdministration, IntranasalAmoxicillinAnimalsCytokinesFemaleImmunity, InnateLungMiceMice, Inbred C57BLToll-Like Receptor 5AmoxicillinAnti-Bacterial AgentsCytokinesFlagellinToll-Like Receptor 5depositionflagellininhalationintranasalnebulizationpneumococcal pneumoniavibrating mesh nebulizer

Identifiers

PMID39480071
PMCPMC11619323

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.